Within days of securing approval for the adult version, Apotex has landed a second win. This time, it’s the pediatric formulation of a widely used parenteral nutrition product.
The U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for generic Infuvite Pediatric Injection—complete with a valuable 180-day Competitive Generic Therapy (CGT) exclusivity for the single-dose vial.
This isn’t just another generic launch. It’s a coordinated, two-step market entry.
In short: faster access, fewer competitors, at least for six months.
This approval is the result of a three-way collaboration:
Each partner played a distinct role in navigating a technically demanding product.
Sterile injectable multivitamins are not simple generics.
This isn’t a “copy and paste” generic. It requires tight coordination across R&D, regulatory, and manufacturing.
Apotex announced approval for the adult version just days earlier. That timing is deliberate.
This is less about a single product—and more about owning a category.
A global generics player headquartered in Florida, focused on improving access to affordable medicines. The company operates across both pharmaceuticals and consumer health.
A B2B specialty pharma firm specializing in complex generics. Known for integrating development, analytics, and regulatory execution.
An injectable powerhouse based in Hyderabad. With operations in over 60 countries, Gland has built scale in sterile manufacturing across formats like vials, syringes, and lyophilized products.
This dual approval highlights a broader shift:
For buyers and hospital systems, it means expanded access. For competitors, it raises the bar.
Apotex didn’t just launch a product. It executed a playbook:
Expect more companies to follow this model—especially in sterile injectables, where barriers are high and rewards are concentrated.